



Microwave-assisted synthesis and antifungal activity of calix[4]aldimines

Cleiton M. da Silva^{1*}, Thais F.F. Magalhães², Danielle L. da Silva², Rosemeire B. Alves¹, Maria A. de Resende-Stoianoff², Ângelo de Fátima¹

¹Grupo de Estudos em Química Orgânica e Biológica (GEQOB), Departamento de Química, ICEx, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

²Departamento de Microbiologia, ICB, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.

*E-mail corresponding author: cleitonms@ufmg.br


Keywords: calixarene, aldimine, antifungal activity.

INTRODUCTION


Calixarenes are macrocyclic compounds formed of phenolic units linked by methylene bridges in *ortho* positions. In last decades these compounds have received increasing attention due to its technological and biological applications, particularly as platforms for the development of new drugs¹. Aldimines are organic substances known to exhibit a broad range of biological properties that includes antifungal, antibacterial, antimalarial, anti-inflammatory and antiviral activities². Here we report the microwave-assisted synthesis of six calix[4]aldimines and their respective monomeric units. The antifungal activities of such compounds against six strains of *Candida* species are also described.

RESULTS AND DISCUSSION

The calix[4]aldimines **6-11** and the aldimines **14-19** were obtained according to the synthetic approach shown in Schemes 1 and 2.



Scheme 1. Synthesis of calix[4]aldimines **6-11**. i) diphenyl ether, NaOH, 260°C, 56%; ii) AlCl₃, toluene, r.t., 80%; iii) NaH, *n*-BuBr, DMF, 80°C, 60%; iv) HOAc/HNO₃, r.t., 54%; v) N₂H₄·H₂O, Pd/C, EtOH, 80°C, 99%; vi) ArCHO, EtOH, microwave irradiation, 52-90%.



Scheme 2. Synthesis of the aldimines **14-19**. i) K₂CO₃, *n*-BuBr, MeCN, 80°C, 94%; ii) N₂H₄·H₂O, Pd/C, EtOH, 80°C, 99%; iii) ArCHO, EtOH, microwave irradiation, 69-88%.

The minimum inhibitory concentration (MIC) for each synthesized compound was determined according to

the protocol M27-A2³. The results are shown in Table 1. In general, both the calix[4]aldimines and aldimines presented moderate activity against the fungi studied. Among all the compounds evaluated, the calix[4]aldimine **11**, derived from 5-nitrofurfuraldehyde, was the most active, with MIC values of 0.05 mmol.L⁻¹ against *C. albicans*, *C. krusei*, *C. tropicalis*, *C. parapsilosis* and *C. dubliniensis*.

Table 1. Minimal inhibitory concentration (MIC; mmol.L⁻¹) of the compounds **6-11** and **14-19** against fungal strains

Fungal strains ^a	Compounds												
	6	7	8	9	10	11	14	15	16	17	18	19	Flu ^b
<i>C.a.</i>	0.48	0.45	0.41	0.45	0.41	0.05	2.02	1.90	1.72	3.77	3.44	1.78	0.0008
<i>C.k.</i>	0.48	0.23	0.21	0.23	0.21	0.05	1.01	1.90	0.86	3.77	1.72	0.22	0.10
<i>C.t.</i>	0.48	0.45	0.41	0.45	0.41	0.05	4.04	3.80	3.43	3.77	3.44	1.78	0.0008
<i>C.p.</i>	0.24	0.11	0.21	0.23	0.41	0.05	1.01	0.48	0.43	3.77	1.72	1.78	0.007
<i>C.g.</i>	0.48	0.23	0.21	0.45	0.41	0.11	4.04	0.95	3.43	3.77	3.44	1.78	0.03
<i>C.d.</i>	0.24	0.45	0.21	0.23	0.41	0.05	2.02	1.90	1.72	3.77	1.72	0.89	0.0008

^aFungal strains: *C. albicans* (C.a.); *C. krusei* (C.k.); *C. tropicalis* (C.t.); *C. parapsilosis* (C.p.); *C. glabrata* (C.g.); *C. dubliniensis* (C.d.). ^bFlu stands for fluconazole (positive control).

CONCLUSION

Six calix[4]aldimines, as well as the respective monomeric units were synthesized and evaluated for their antifungal activities. *In vitro* assays showed that calix[4]aldimine **11** is an interesting lead compound for the development of new antifungal agents.

ACKNOWLEDGEMENTS

The authors thank FAPEMIG, CAPES and CNPq for financial support.

REFERENCES

- de Fátima, A.; Fernandes, S. A.; Sabino, A. A. *Curr. Drug. Discov. Tech.* **2009**, 6, 151.
- da Silva, C. M.; da Silva, D. L.; Modolo, L. V.; Alves, R. B.; Martins, C. V. B.; de Resende, M. A.; de Fátima, A. J. *Adv. Res.* **2011**, 2, 1.
- Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved standard, 2nd ed. NCCLS document M27-A2. Villanova: Clinical and Laboratory Standards Institute. **2002**.